Stocks and Investing
Stocks and Investing
Thu, August 11, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, August 10, 2022
[ 12:00 AM ] - WOPRAI
Luca Issi Maintained (ALLO) at Buy with Decreased Target to $32 on, Aug 10th, 2022
Luca Issi of RBC Capital, Maintained "Allogene Therapeutics, Inc." (ALLO) at Buy with Decreased Target from $35 to $32 on, Aug 10th, 2022.
Luca has made no other calls on ALLO in the last 4 months.
There are 2 other peers that have a rating on ALLO. Out of the 2 peers that are also analyzing ALLO, 1 agrees with Luca's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jack Allen of "Baird" Initiated at Hold and Held Target at $11 on, Friday, June 3rd, 2022
This is the rating of the analyst that currently disagrees with Luca
- Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $32 on, Friday, July 15th, 2022
Contributing Sources